Brepocitinib Launch Lead

Job description

ROLE SUMMARY: The International Commercial Office will establish a commercial operating model for Brepocitinib, a TYK2/JAK1 inhibitor. Our initial indication (pending regulatory approval) is focused on dermatomyositis, a rare chronic systemic autoimmune disease characterized by muscle weakness and skin rashes. The International Launch Lead position is critical to enabling a successful international launch and sustained growth of Brepocitinib, to drive a best in class launch for a drug that has the potential to bring meaningful difference to patients currently lacking adequate therapy. Brepocitinib is a priority brand within the ICO portfolio with significant opportunity to drive impact for patients and sustainable growth for Pfizer. As Pfizer has the ex-US and ex-Japan rights, ICO will lead the end-to-end launch of Brepo across all International markets. - This is a critical role leading the overarching International Launch plan & being the key contact for countries on launch planning & the execution of their launch plans. - Lead on forecasting for the initial DM indication, as well as taking the lead on building out the forecasting for the further indications for the brand to come...